MDT discussions on the rationale for using GLP-1 as a therapeutic target in T2D episode artwork

EPISODE · Apr 14, 2022 · 13 MIN

MDT discussions on the rationale for using GLP-1 as a therapeutic target in T2D

from touchPODCAST · host touchpodcast

touchMDT for touchENDOCRINOLOGY Listen to key experts from a multidisciplinary team review the rationale for using GLP-1 as a therapeutic target in T2D and provide an overview of GLP-1 RA based therapies  The multidisciplinary team Primary Care Physician: Dr Kevin Fernando, Berwick, UK Endocrinologist: Prof. Dr med. Michael Nauck, Bochum, Germany This touchPODCAST is for HCPs only. This activity is funded by an unrestricted independent medical education grant from Novo Nordisk A/S. This activity is jointly provided by USF Health and touchIME. For further information visit our website: https://touchendocrinologyime.org/mdt-integrating-glp1ras-t2d-management-from-pcp-to-patient/  

Episode metadata supplied by the publisher feed · Published Apr 14, 2022

Embed this episode

Ready to play

MDT discussions on the rationale for using GLP-1 as a therapeutic target in T2D

0:00 13:52

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of touchPODCAST?

This episode is 13 minutes long.

When was this touchPODCAST episode published?

This episode was published on April 14, 2022.

Can I download this touchPODCAST episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!